Evaluation of replication and cross-reactive antibody responses of H2 subtype influenza viruses in mice and ferrets.
Identifieur interne : 000198 ( PubMed/Corpus ); précédent : 000197; suivant : 000199Evaluation of replication and cross-reactive antibody responses of H2 subtype influenza viruses in mice and ferrets.
Auteurs : Grace L. Chen ; Elaine W. Lamirande ; Chin-Fen Yang ; Hong Jin ; George Kemble ; Kanta SubbaraoSource :
- Journal of virology [ 1098-5514 ] ; 2010.
English descriptors
- KwdEn :
- Animals, Antibodies, Neutralizing (immunology), Antibodies, Viral (blood), Cross Reactions, Female, Ferrets, Hemagglutination Inhibition Tests, Influenza A Virus, H2N2 Subtype (growth & development), Influenza A Virus, H2N2 Subtype (immunology), Influenza A virus (growth & development), Influenza A virus (immunology), Mice, Mice, Inbred BALB C, Neutralization Tests.
- MESH :
- chemical , blood : Antibodies, Viral.
- chemical , immunology : Antibodies, Neutralizing.
- growth & development : Influenza A Virus, H2N2 Subtype, Influenza A virus.
- immunology : Influenza A Virus, H2N2 Subtype, Influenza A virus.
- Animals, Cross Reactions, Female, Ferrets, Hemagglutination Inhibition Tests, Mice, Mice, Inbred BALB C, Neutralization Tests.
Abstract
H2 influenza viruses have not circulated in humans since 1968, and therefore a large segment of the population would likely be susceptible to infection should H2 influenza viruses reemerge. The development of an H2 pandemic influenza virus vaccine candidate should therefore be considered a priority in pandemic influenza preparedness planning. We selected a group of geographically and temporally diverse wild-type H2 influenza viruses and evaluated the kinetics of replication and compared the ability of these viruses to induce a broadly cross-reactive antibody response in mice and ferrets. In both mice and ferrets, A/Japan/305/1957 (H2N2), A/mallard/NY/1978 (H2N2), and A/swine/MO/2006 (H2N3) elicited the broadest cross-reactive antibody responses against heterologous H2 influenza viruses as measured by hemagglutination inhibition and microneutralization assays. These data suggested that these three viruses may be suitable candidates for development as live attenuated H2 pandemic influenza virus vaccines.
DOI: 10.1128/JVI.00511-10
PubMed: 20504935
Links to Exploration step
pubmed:20504935Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Evaluation of replication and cross-reactive antibody responses of H2 subtype influenza viruses in mice and ferrets.</title>
<author><name sortKey="Chen, Grace L" sort="Chen, Grace L" uniqKey="Chen G" first="Grace L" last="Chen">Grace L. Chen</name>
<affiliation><nlm:affiliation>Laboratory of Infectious Diseases, NIAID, NIH, Bethesda, Maryland 20892-3203, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Lamirande, Elaine W" sort="Lamirande, Elaine W" uniqKey="Lamirande E" first="Elaine W" last="Lamirande">Elaine W. Lamirande</name>
</author>
<author><name sortKey="Yang, Chin Fen" sort="Yang, Chin Fen" uniqKey="Yang C" first="Chin-Fen" last="Yang">Chin-Fen Yang</name>
</author>
<author><name sortKey="Jin, Hong" sort="Jin, Hong" uniqKey="Jin H" first="Hong" last="Jin">Hong Jin</name>
</author>
<author><name sortKey="Kemble, George" sort="Kemble, George" uniqKey="Kemble G" first="George" last="Kemble">George Kemble</name>
</author>
<author><name sortKey="Subbarao, Kanta" sort="Subbarao, Kanta" uniqKey="Subbarao K" first="Kanta" last="Subbarao">Kanta Subbarao</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2010">2010</date>
<idno type="RBID">pubmed:20504935</idno>
<idno type="pmid">20504935</idno>
<idno type="doi">10.1128/JVI.00511-10</idno>
<idno type="wicri:Area/PubMed/Corpus">000198</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000198</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Evaluation of replication and cross-reactive antibody responses of H2 subtype influenza viruses in mice and ferrets.</title>
<author><name sortKey="Chen, Grace L" sort="Chen, Grace L" uniqKey="Chen G" first="Grace L" last="Chen">Grace L. Chen</name>
<affiliation><nlm:affiliation>Laboratory of Infectious Diseases, NIAID, NIH, Bethesda, Maryland 20892-3203, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Lamirande, Elaine W" sort="Lamirande, Elaine W" uniqKey="Lamirande E" first="Elaine W" last="Lamirande">Elaine W. Lamirande</name>
</author>
<author><name sortKey="Yang, Chin Fen" sort="Yang, Chin Fen" uniqKey="Yang C" first="Chin-Fen" last="Yang">Chin-Fen Yang</name>
</author>
<author><name sortKey="Jin, Hong" sort="Jin, Hong" uniqKey="Jin H" first="Hong" last="Jin">Hong Jin</name>
</author>
<author><name sortKey="Kemble, George" sort="Kemble, George" uniqKey="Kemble G" first="George" last="Kemble">George Kemble</name>
</author>
<author><name sortKey="Subbarao, Kanta" sort="Subbarao, Kanta" uniqKey="Subbarao K" first="Kanta" last="Subbarao">Kanta Subbarao</name>
</author>
</analytic>
<series><title level="j">Journal of virology</title>
<idno type="eISSN">1098-5514</idno>
<imprint><date when="2010" type="published">2010</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term>
<term>Antibodies, Neutralizing (immunology)</term>
<term>Antibodies, Viral (blood)</term>
<term>Cross Reactions</term>
<term>Female</term>
<term>Ferrets</term>
<term>Hemagglutination Inhibition Tests</term>
<term>Influenza A Virus, H2N2 Subtype (growth & development)</term>
<term>Influenza A Virus, H2N2 Subtype (immunology)</term>
<term>Influenza A virus (growth & development)</term>
<term>Influenza A virus (immunology)</term>
<term>Mice</term>
<term>Mice, Inbred BALB C</term>
<term>Neutralization Tests</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Antibodies, Viral</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Antibodies, Neutralizing</term>
</keywords>
<keywords scheme="MESH" qualifier="growth & development" xml:lang="en"><term>Influenza A Virus, H2N2 Subtype</term>
<term>Influenza A virus</term>
</keywords>
<keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Influenza A Virus, H2N2 Subtype</term>
<term>Influenza A virus</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Animals</term>
<term>Cross Reactions</term>
<term>Female</term>
<term>Ferrets</term>
<term>Hemagglutination Inhibition Tests</term>
<term>Mice</term>
<term>Mice, Inbred BALB C</term>
<term>Neutralization Tests</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">H2 influenza viruses have not circulated in humans since 1968, and therefore a large segment of the population would likely be susceptible to infection should H2 influenza viruses reemerge. The development of an H2 pandemic influenza virus vaccine candidate should therefore be considered a priority in pandemic influenza preparedness planning. We selected a group of geographically and temporally diverse wild-type H2 influenza viruses and evaluated the kinetics of replication and compared the ability of these viruses to induce a broadly cross-reactive antibody response in mice and ferrets. In both mice and ferrets, A/Japan/305/1957 (H2N2), A/mallard/NY/1978 (H2N2), and A/swine/MO/2006 (H2N3) elicited the broadest cross-reactive antibody responses against heterologous H2 influenza viruses as measured by hemagglutination inhibition and microneutralization assays. These data suggested that these three viruses may be suitable candidates for development as live attenuated H2 pandemic influenza virus vaccines.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">20504935</PMID>
<DateCompleted><Year>2010</Year>
<Month>07</Month>
<Day>20</Day>
</DateCompleted>
<DateRevised><Year>2018</Year>
<Month>11</Month>
<Day>13</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1098-5514</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>84</Volume>
<Issue>15</Issue>
<PubDate><Year>2010</Year>
<Month>Aug</Month>
</PubDate>
</JournalIssue>
<Title>Journal of virology</Title>
<ISOAbbreviation>J. Virol.</ISOAbbreviation>
</Journal>
<ArticleTitle>Evaluation of replication and cross-reactive antibody responses of H2 subtype influenza viruses in mice and ferrets.</ArticleTitle>
<Pagination><MedlinePgn>7695-702</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1128/JVI.00511-10</ELocationID>
<Abstract><AbstractText>H2 influenza viruses have not circulated in humans since 1968, and therefore a large segment of the population would likely be susceptible to infection should H2 influenza viruses reemerge. The development of an H2 pandemic influenza virus vaccine candidate should therefore be considered a priority in pandemic influenza preparedness planning. We selected a group of geographically and temporally diverse wild-type H2 influenza viruses and evaluated the kinetics of replication and compared the ability of these viruses to induce a broadly cross-reactive antibody response in mice and ferrets. In both mice and ferrets, A/Japan/305/1957 (H2N2), A/mallard/NY/1978 (H2N2), and A/swine/MO/2006 (H2N3) elicited the broadest cross-reactive antibody responses against heterologous H2 influenza viruses as measured by hemagglutination inhibition and microneutralization assays. These data suggested that these three viruses may be suitable candidates for development as live attenuated H2 pandemic influenza virus vaccines.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chen</LastName>
<ForeName>Grace L</ForeName>
<Initials>GL</Initials>
<AffiliationInfo><Affiliation>Laboratory of Infectious Diseases, NIAID, NIH, Bethesda, Maryland 20892-3203, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Lamirande</LastName>
<ForeName>Elaine W</ForeName>
<Initials>EW</Initials>
</Author>
<Author ValidYN="Y"><LastName>Yang</LastName>
<ForeName>Chin-Fen</ForeName>
<Initials>CF</Initials>
</Author>
<Author ValidYN="Y"><LastName>Jin</LastName>
<ForeName>Hong</ForeName>
<Initials>H</Initials>
</Author>
<Author ValidYN="Y"><LastName>Kemble</LastName>
<ForeName>George</ForeName>
<Initials>G</Initials>
</Author>
<Author ValidYN="Y"><LastName>Subbarao</LastName>
<ForeName>Kanta</ForeName>
<Initials>K</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y"><Grant><Agency>Intramural NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052060">Research Support, N.I.H., Intramural</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2010</Year>
<Month>05</Month>
<Day>26</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>J Virol</MedlineTA>
<NlmUniqueID>0113724</NlmUniqueID>
<ISSNLinking>0022-538X</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D057134" MajorTopicYN="N">Antibodies, Neutralizing</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName>
<QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D003429" MajorTopicYN="N">Cross Reactions</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005289" MajorTopicYN="N">Ferrets</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006385" MajorTopicYN="N">Hemagglutination Inhibition Tests</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D053121" MajorTopicYN="N">Influenza A Virus, H2N2 Subtype</DescriptorName>
<QualifierName UI="Q000254" MajorTopicYN="N">growth & development</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D009980" MajorTopicYN="N">Influenza A virus</DescriptorName>
<QualifierName UI="Q000254" MajorTopicYN="Y">growth & development</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008807" MajorTopicYN="N">Mice, Inbred BALB C</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D009500" MajorTopicYN="N">Neutralization Tests</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year>
<Month>5</Month>
<Day>28</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2010</Year>
<Month>5</Month>
<Day>28</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2010</Year>
<Month>7</Month>
<Day>21</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">20504935</ArticleId>
<ArticleId IdType="pii">JVI.00511-10</ArticleId>
<ArticleId IdType="doi">10.1128/JVI.00511-10</ArticleId>
<ArticleId IdType="pmc">PMC2897620</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>J Gen Virol. 1999 Dec;80 ( Pt 12):3167-71</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10567648</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Virology. 2010 Mar 1;398(1):109-14</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20034647</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Bull World Health Organ. 1999;77(10):820-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10593030</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Annu Rev Med. 2000;51:407-21</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10774473</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Arch Virol. 2000;145(5):885-93</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10881676</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Arch Virol. 2000;145(6):1059-66</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10948982</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Virology. 2003 Jan 20;305(2):267-75</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12573572</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Med Virol. 2003 Jul;70(3):391-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12767002</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Virus Genes. 2004 Aug;29(1):81-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15215686</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Gen Virol. 2004 Aug;85(Pt 8):2327-37</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15269374</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Infect Dis. 2004 Oct 1;39(7):920-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15472840</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Am J Epidemiol. 1966 Jan;83(1):101-12</Citation>
<ArticleIdList><ArticleId IdType="pubmed">5910213</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Hyg (Lond). 1977 Oct;79(2):203-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">269196</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Virology. 1978 Jun 1;87(1):13-20</Citation>
<ArticleIdList><ArticleId IdType="pubmed">664248</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Infect Immun. 1981 Nov;34(2):354-61</Citation>
<ArticleIdList><ArticleId IdType="pubmed">7309229</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Infect Dis. 1982 Mar;145(3):320-30</Citation>
<ArticleIdList><ArticleId IdType="pubmed">6977595</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Infect Immun. 1982 Sep;37(3):1119-26</Citation>
<ArticleIdList><ArticleId IdType="pubmed">7129631</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 1989 Nov;63(11):4603-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">2795713</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Virology. 1993 Jun;194(2):781-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">7684877</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Arch Virol. 1994;135(1-2):101-14</Citation>
<ArticleIdList><ArticleId IdType="pubmed">8198436</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Acta Virol. 1997 Oct;41(5):251-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">9607078</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS Med. 2006 Sep;3(9):e360</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16968127</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Avian Dis. 2007 Mar;51(1 Suppl):425-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17494599</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS Pathog. 2007 May 11;3(5):e61</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17500589</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2007 Oct;81(19):10558-66</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17634234</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Antivir Ther. 2007;12(4 Pt B):581-91</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17944266</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS Pathog. 2007 Nov;3(11):e167</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17997603</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Proc Natl Acad Sci U S A. 2007 Dec 26;104(52):20949-54</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18093945</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Virus Genes. 2008 Aug;37(1):16-21</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18454312</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2008 Nov;82(21):10854-63</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18715930</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2009 Jun 18;360(25):2605-15</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19423869</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 1999 Dec 10;18(9-10):899-906</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10580204</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/H2N2V1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000198 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 000198 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= H2N2V1 |flux= PubMed |étape= Corpus |type= RBID |clé= pubmed:20504935 |texte= Evaluation of replication and cross-reactive antibody responses of H2 subtype influenza viruses in mice and ferrets. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:20504935" \ | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \ | NlmPubMed2Wicri -a H2N2V1
![]() | This area was generated with Dilib version V0.6.33. | ![]() |